ORIC PHARMACEUTICALS, INC. Restricted Cash and Cash Equivalents
ORIC PHARMACEUTICALS, INC. (ORIC) had Restricted Cash and Cash Equivalents of $491.00 thousand as of 2026-06-30, per its 10-Q filed 2026-08-03.
Financial Statements › Balance Sheet › Assets
us-gaap:RestrictedCashAndCashEquivalents · last filed 2026-08-03
- 2026-06-30: Restricted Cash and Cash Equivalents $491.00K.
- 2026-03-31: Restricted Cash and Cash Equivalents $491.00K.
- 2025-12-31: Restricted Cash and Cash Equivalents $491.00K.
- 2025-09-30: Restricted Cash and Cash Equivalents $491.00K.
| Period end | Restricted Cash and Cash Equivalents |
|---|---|
| 2026-06-30 | $491.00K 10-Q · filed 2026-08-03 |
| 2026-03-31 | $491.00K 10-Q · filed 2026-05-04 |
| 2025-12-31 | $491.00K 10-K · filed 2026-02-23 |
| 2025-09-30 | $491.00K 10-Q · filed 2025-11-13 |
| 2025-06-30 | $491.00K 10-Q · filed 2026-08-03 |
| 2025-03-31 | $491.00K 10-Q · filed 2026-05-04 |
| 2024-12-31 | $491.00K 10-K · filed 2026-02-23 |
| 2024-09-30 | $491.00K 10-Q · filed 2025-11-13 |
| 2024-06-30 | $491.00K 10-Q · filed 2025-08-12 |
| 2024-03-31 | $491.00K 10-Q · filed 2025-05-05 |
| 2023-12-31 | $491.00K 10-K · filed 2025-02-18 |
| 2023-09-30 | $491.00K 10-Q · filed 2024-11-12 |
| 2023-06-30 | $491.00K 10-Q · filed 2024-08-12 |
| 2023-03-31 | $468.00K 10-Q · filed 2024-05-06 |
| 2022-12-31 | $468.00K 10-K · filed 2024-03-11 |
| 2022-09-30 | $468.00K 10-Q · filed 2023-11-06 |
| 2022-06-30 | $468.00K 10-Q · filed 2023-08-10 |
| 2022-03-31 | $468.00K 10-Q · filed 2023-05-08 |
| 2021-12-31 | $468.00K 10-K · filed 2023-03-16 |
| 2021-09-30 | $468.00K 10-Q · filed 2022-11-07 |
| 2021-06-30 | $0.00 10-Q · filed 2022-08-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kardigan, Inc. (KARD) | United States | $1.346B | |
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| Damora Therapeutics, Inc. (DMRA) | $1.250B | -6.10 | |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |